PURPOSE:Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes. METHODS: This placebo-controlled, double-blinded trial enrolled rash-free patients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks. RESULTS: Fifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78%) and 39 (80%) sunscreen-treated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p = .20). Quality of life scores declined but remained comparable between arms. CONCLUSIONS:Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.
RCT Entities:
PURPOSE:Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes. METHODS: This placebo-controlled, double-blinded trial enrolled rash-freepatients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks. RESULTS: Fifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78%) and 39 (80%) sunscreen-treated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p = .20). Quality of life scores declined but remained comparable between arms. CONCLUSIONS: Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.
Authors: Minnelly Luu; Susan E Lai; Jyoti Patel; Joan Guitart; Mario E Lacouture Journal: Photodermatol Photoimmunol Photomed Date: 2007-02 Impact factor: 3.135
Authors: Aminah Jatoi; Kendrith Rowland; Jeff A Sloan; Howard M Gross; Paul A Fishkin; Stephen P Kahanic; Paul J Novotny; Paul L Schaefer; David B Johnson; Loren K Tschetter; Charles L Loprinzi Journal: Cancer Date: 2008-08-15 Impact factor: 6.860
Authors: Alon Scope; Anna Liza C Agero; Stephen W Dusza; Patricia L Myskowski; Jocelyn A Lieb; Leonard Saltz; Nancy E Kemeny; Allan C Halpern Journal: J Clin Oncol Date: 2007-12-01 Impact factor: 44.544
Authors: Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy Journal: Support Care Cancer Date: 2011-06-01 Impact factor: 3.603
Authors: J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover Journal: Invest New Drugs Date: 2021-01-03 Impact factor: 3.651